Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia

Blood

Volumn 100, Issue 5, 2002, Pages 1566-1569

  Wanless, Ian R ^{a,b,c,d,e,f,g,h,i,j}   Sweeney, George ^{a,b,c,d,e,f,g,h,i}   Dhillon, Amar P ^{a,b,c,d,e,f,g,h,i}   Guido, Maria ^{a,b,c,d,e,f,g,h,i}   Piga, Antonio ^{a,b,c,d,e,f,g,h,i}   Galanello, Renzo ^{a,b,c,d,e,f,g,h,i}   Rita Gamberini, M ^{a,b,c,d,e,f,g,h,i}   Schwartz, Elias ^{a,b,c,d,e,f,g,h,i}   Cohen, Alan R ^{a,b,c,d,e,f,g,h,i}  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f Instituto di Clinica e Biologia dell'Eta'Evolutiva   (Italy)

^g Azienda OspedalieraUniversitaria S Anna   (Italy)

^h THOMAS JEFFERSON UNIVERSITY   (United States)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^j TORONTO GENERAL HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0036721452     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0306     Document Type: Article

References (29)

1. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine
2. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients
3. Results of long-term iron chelating therapy
4. Survival in betathalassaemia major in the UK: Data from the UK Thalassaemia Register
5. New orally active iron chelators
6. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one
7. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1)
8. Deferiprone: A review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases
9. Iron complexes of deferlprone and dietary plant catechols as cytoprotective superoxide radical scavengers
10. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
11. Combined therapy with deferiprone and desferrioxamine
12. Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major
13. Safety profile of the oral iron chelator deferiprone: A multicentre study
14. Iron chelation with oral deferiprone in patients with thalassemia
15. Iron chelation with oral deferiprone in patients with thalassemia
16. Liver Iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients
17. No progression of liver fibrosis in thalassemia major during deferiprone or desferrioxomine iron chelation
18. Sequential liver fibrosis grading during deferiprone treatment in patients with thalassemia major
19. The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1)
20. Histological grading and staging of chronic hepatitis
21. The Laennec grading system for assessment of hepatic fibrosis: Validation by correlation with wedged hepatic vein pressure and clinical features
22. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C
23. A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia: A six-year study
24. Long-term safety and efficacy of the oral iron chelator deferiprone
25. Natural history of liver fibrosis progression in patients with chronic hepatitis C
26. Iron chelation with oral deferiprone in patients with thalassemia
27. Iron-chelation therapy with oral deferiprone: Toxicity or lack of efficacy?